中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.031 seconds)

    Humanized Antibody
    3.
    发明申请
    Humanized Antibody 审中-公开
    人源化抗体

    公开(公告)号：US20160244514A1

    公开(公告)日：2016-08-25

    申请号：US14978113

    申请日：2015-12-22

    Applicant: Genentech, Inc. ,  AC Immune S.A.

    Inventor： Andrea Pfeifer ,  Maria Pihlgren ,  Andreas Muhs ,  Ryan Watts

    IPC: C07K16/18 ,  A61K49/00

    CPC classification number: C07K16/18 ,  A61K49/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

    Abstract: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.

    Abstract translation: 本发明提供新的方法和组合物，其包含特异性识别并结合来自β-淀粉样蛋白范围的特异性表位的高度特异性和高效抗体。 本发明的抗体特别可用于治疗与视觉系统的组织中的病理学异常/变化相关的眼部疾病，特别是与视觉系统的组织中淀粉样蛋白-β相关的病理学异常/变化相关。

    Monoclonal Antibody
    4.
    发明申请
    Monoclonal Antibody 有权
    单克隆抗体

    公开(公告)号：US20160000910A1

    公开(公告)日：2016-01-07

    申请号：US14861001

    申请日：2015-09-22

    Applicant: AC IMMUNE S.A. ,  GENENTECH, INC.

    Inventor： Andrea Pfeifer ,  Maria Pihlgren ,  Andreas Muhs ,  Ryan Watts

    IPC: A61K39/395 ,  C07K14/47 ,  G01N33/68 ,  C07K16/18 ,  A61K45/06

    CPC classification number: A61K39/3955 ,  A61K31/5513 ,  A61K45/06 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/4711 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52

    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

    Abstract translation: 本发明涉及用于治疗和诊断用途的方法和组合物，所述方法和组合物用于治疗由淀粉样蛋白或淀粉状蛋白样蛋白质引起或与之相关的疾病和病症，包括淀粉样变性，与淀粉样蛋白相关的一组障碍和异常，例如 阿尔茨海默氏病。 本发明提供了包含高度特异性和高效抗体的新型方法和组合物，其具有特异性识别并结合来自一系列淀粉样蛋白质的特定表位的能力。 通过本发明的教导实现的抗体特别可用于治疗由淀粉样蛋白或淀粉样蛋白样蛋白引起或与之相关的疾病和病症，包括淀粉样变性，与淀粉样斑块形成相关的一组疾病和病症，包括继发性淀粉样变性 和年龄相关的淀粉样变性病，包括但不限于神经障碍如阿尔茨海默病（AD）。

    Monoclonal antibody
    5.
    发明授权
    Monoclonal antibody 有权
    单克隆抗体

    公开(公告)号：US09175094B2

    公开(公告)日：2015-11-03

    申请号：US14077915

    申请日：2013-11-12

    Applicant: AC Immune S.A. ,  Genentech, Inc.

    Inventor： Andrea Pfeifer ,  Maria Pihlgren ,  Andreas Muhs ,  Ryan Watts

    IPC: A61K39/395 ,  C07K16/18 ,  A61K45/06 ,  C07K16/44 ,  G01N33/68 ,  A61K31/5513 ,  A61K39/00

    CPC classification number: A61K39/3955 ,  A61K31/5513 ,  A61K45/06 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/4711 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52

    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

    Abstract translation: 本发明涉及用于治疗和诊断用途的方法和组合物，所述方法和组合物用于治疗由淀粉样蛋白或淀粉样蛋白样蛋白质引起或与之相关的疾病和病症，包括淀粉样变性，与淀粉样蛋白相关的一组障碍和异常，例如 阿尔茨海默氏病。 本发明提供了包含高度特异性和高效抗体的新型方法和组合物，其具有特异性识别并结合来自一系列淀粉样蛋白质的特定表位的能力。 通过本发明的教导实现的抗体特别可用于治疗由淀粉样蛋白或淀粉样蛋白样蛋白引起或与之相关的疾病和病症，包括淀粉样变性，与淀粉样斑块形成相关的一组疾病和病症，包括继发性淀粉样变性 和年龄相关的淀粉样变性病，包括但不限于神经障碍如阿尔茨海默病（AD）。

Patent Agency Ranking